IMA

Company Overview — What Does Ikena Oncology, Inc. Do?

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. Ikena Oncology, Inc. (IMA) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Mark Manfredi and employs approximately 70 people. With a market capitalization of $56M, IMA is one of the notable companies in the Healthcare sector.

Ikena Oncology, Inc. (IMA) Stock Rating — Reduce (April 2026)

As of April 2026, Ikena Oncology, Inc. receives a Reduce rating with a composite score of 33.6/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.IMA ranks #3,195 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Ikena Oncology, Inc. ranks #481 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

IMA Stock Price and 52-Week Range

Ikena Oncology, Inc. (IMA) currently trades at $4.90. The stock gained $0.15 (3.2%) in the most recent trading session. The 52-week high for IMA is $18.00, which means the stock is currently trading -72.8% from its annual peak. The 52-week low is $0.97, putting the stock 405.0% above its annual trough. Recent trading volume was 5K shares, suggesting relatively thin trading activity.

Is IMA Overvalued or Undervalued? — Valuation Analysis

Ikena Oncology, Inc. (IMA) carries a value factor score of 11/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.40x, versus the sector average of 2.75x. The price-to-sales ratio is 15.18x, compared to 1.66x for the average Healthcare stock.

At current multiples, Ikena Oncology, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Ikena Oncology, Inc. Profitability — ROE, Margins, and Quality Score

Ikena Oncology, Inc. (IMA) earns a quality factor score of 22/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -29.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -25.7% versus the sector average of -33.1%.

On a margin basis, Ikena Oncology, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -58.2% (sector: -66.1%). Net profit margin stands at -90.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -100.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

IMA Debt, Balance Sheet, and Financial Health

Ikena Oncology, Inc. has a debt-to-equity ratio of 15.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 12.49x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $103M.

IMA has a beta of 0.42, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Ikena Oncology, Inc. is 33/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Ikena Oncology, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Ikena Oncology, Inc. reported revenue of $4M and earnings per share (EPS) of $-9.64. Net income for the quarter was $-39M. Gross margin was 100.0%. Operating income came in at $-48M.

In FY 2025, Ikena Oncology, Inc. reported revenue of $800,000 and earnings per share (EPS) of $-9.64. Net income for the quarter was $-45M. Operating income came in at $-48M.

In Q3 2025, Ikena Oncology, Inc. reported revenue of $0 and earnings per share (EPS) of $-2.91. Net income for the quarter was $-25M. Operating income came in at $-27M.

In Q2 2025, Ikena Oncology, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.06. Net income for the quarter was $-3M. Operating income came in at $-9M.

Over the past 8 quarters, Ikena Oncology, Inc. has demonstrated a growth trajectory, with revenue expanding from $0 to $4M. Investors analyzing IMA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

IMA Dividend Yield and Income Analysis

Ikena Oncology, Inc. (IMA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

IMA Momentum and Technical Analysis Profile

Ikena Oncology, Inc. (IMA) has a momentum factor score of 51/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 67/100 reflects moderate short selling activity.

IMA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Ikena Oncology, Inc. (IMA) ranks #481 out of 838 stocks based on the Blank Capital composite score. This places IMA in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing IMA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full IMA vs S&P 500 (SPY) comparison to assess how Ikena Oncology, Inc. stacks up against the broader market across all factor dimensions.

IMA Next Earnings Date

No upcoming earnings date has been announced for Ikena Oncology, Inc. (IMA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy IMA? — Investment Thesis Summary

The quantitative profile for Ikena Oncology, Inc. suggests caution. The quality score of 22/100 flags below-average profitability. The value score of 11/100 indicates premium valuation. High volatility (stability score 33/100) increases portfolio risk.

In summary, Ikena Oncology, Inc. (IMA) earns a Reduce rating with a composite score of 33.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on IMA stock.

Related Resources for IMA Investors

Explore more research and tools: IMA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare IMA head-to-head with peers: IMA vs AZN, IMA vs SLGL, IMA vs VMD.